This milestone was achieved at START Madrid/Fundación Jiménez Díaz University Hospital.

“TH9619 embodies our unique strategy of targeting one-carbon metabolism proteins, by killing cancer cells while sparing normal cells and bringing new hope to subjects with high unmet medical need. We are deeply grateful to the investigators, clinical teams, our collaborators, and most importantly, the subjects who make this progress possible,” says Ana Slipicevic, Chief Executive Officer of One-carbon Therapeutics.

About ODIN Phase 1/2 clinical study 

This is a first in human, multicenter, open label, dose escalation and expansion study, aiming at evaluating safety, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of TH9619 as monotherapy in subjects with advanced refractory solid tumors, including colorectal cancer, non-small cell lung cancer, head & neck squamous cell carcinoma, gastric cancer or gastroesophageal junction cancer.

The trial is currently being conducted across academic and clinical research centers in the United Kingdom, France, and Spain, with expansion planned across additional European sites in the coming months.